InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
Portfolio Pulse from
InflaRx N.V. (Nasdaq: IFRX) has received a positive opinion from the CHMP of the EMA for its drug GOHIBIC (vilobelimab) for treating SARS-CoV-2-induced ARDS. The European Commission is expected to issue a marketing authorization soon.
November 15, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
InflaRx has received a positive CHMP opinion for its drug GOHIBIC, which is expected to receive marketing authorization from the European Commission soon.
The positive CHMP opinion is a significant regulatory milestone for InflaRx, indicating a likely approval by the European Commission. This can lead to increased market potential and revenue for the company, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100